Testing and decontamination specialist Bioquell saw its half-year performance hit by the loss of a defence contract. While the shares - which have risen nearly 30 per cent in the past year and now trade at broker Investec's 131p-a-share sum-of-the parts valuation - are looking up with events.
IC TIP:
Hold
at
131p
Although Bioquell has been investing in its future - the group has more than doubled its manufacturing facilities, which should support both product launches and bolster the group's recurring revenues. But the lost defence contract forced revenue at the bio-decontamination side to slide 11 per cent year on year to £11.9m, while the group's order book fell £3m to £20.9m.